IDEXX Laboratories (NASDAQ:IDXX) Posts Quarterly Earnings Results

Key Points

• Q1 beat and upgraded full‑year guidance — IDEXX reported EPS of $3.47 vs. $3.42 consensus and revenue of $1.14B (up 14% y/y), and raised FY‑2026 guidance to EPS $14.45–$14.90 and revenue of roughly $4.675B–$4.76B.
• Operational momentum and margin expansion — Organic revenue grew ~11% (reported +14%), CAG Diagnostics recurring revenue +11%, with strong instrument placements and a ~100bp comparable operating margin gain that drove ~15% comparable EPS growth.
• Near‑term risks: weakening visits and valuation scrutiny — U.S. same‑store clinical visits declined ~1% in Q1 and management now guides ~‑1.5% for the year, which could constrain volume, while elevated valuation multiples and recent insider selling increase execution and valuation concerns.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) posted its earnings results on Tuesday. The company reported $3.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.42 by $0.05, Zacks reports. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The firm had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.12 billion. During the same quarter in the prior year, the business posted $2.91 earnings per share. The business's quarterly revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories updated its FY 2026 guidance to 14.450-14.900 EPS.

Here are the key takeaways from IDEXX Laboratories' conference call:

• Raised full‑year guidance — revenue now $4.675B–$4.76B and EPS $14.45–$14.90, with organic revenue growth guidance of 7.7%–9.7% and CAG Diagnostics recurring growth of 8.7%–10.7%, reflecting a roughly $42M midpoint improvement from Q1 execution.
• Strong Q1 operating performance — revenue +14% reported (+11% organic), CAG Diagnostics recurring revenue +11%, 1,100 InViewDX placements and 28% organic instrument revenue growth, VetLab consumables +15%, and a 100 bp comparable operating margin gain driving 15% comparable EPS growth.
• Demand headwinds in visits — U.S. same‑store clinical visits declined ~1% in Q1 (wellness visits -3%) and the company is guiding to ~-1.5% U.S. clinical visits for the year, which could constrain future volume growth if trends persist.
• One‑time and FX effects — Q1 included a $5M loss on an equity investment (~$0.05 EPS headwind) and a prior litigation expense (~30 bp margin impact), while FX added about $0.14 to EPS; balance sheet remains strong (0.5x net leverage) after $361M of share repurchases.

IDEXX Laboratories Price Performance

NASDAQ:IDXX traded down $0.15 during trading hours on Tuesday, hitting $562.97. 731,078 shares of the company's stock traded hands, compared to its average volume of 525,022. IDEXX Laboratories has a 52 week low of $465.00 and a 52 week high of $769.98. The business's fifty day simple moving average is $589.55 and its two-hundred day simple moving average is $651.34. The company has a quick ratio of 0.90, a current ratio of 1.23 and a debt-to-equity ratio of 0.23. The firm has a market cap of $44.72 billion, a P/E ratio of 43.07, a P/E/G ratio of 3.45 and a beta of 1.58.

Insiders Place Their Bets

In other news, EVP Michael G. Erickson sold 5,371 shares of IDEXX Laboratories stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $627.38, for a total transaction of $3,369,657.98. Following the completion of the sale, the executive vice president owned 12,693 shares in the company, valued at approximately $7,963,334.34. This trade represents a 29.73% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP George Fennell sold 11,345 shares of the business's stock in a transaction dated Tuesday, February 10th. The stock was sold at an average price of $646.72, for a total value of $7,337,038.40. Following the transaction, the executive vice president directly owned 9,823 shares of the company's stock, valued at $6,352,730.56. The trade was a 53.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 45,957 shares of company stock worth $29,862,109. 0.79% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On IDEXX Laboratories

Several hedge funds have recently bought and sold shares of IDXX. Virtus Advisers LLC bought a new position in shares of IDEXX Laboratories in the 3rd quarter worth $26,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of IDEXX Laboratories during the 3rd quarter valued at $36,000. WealthCollab LLC bought a new stake in shares of IDEXX Laboratories during the 2nd quarter worth $30,000. Johnson Financial Group Inc. lifted its holdings in shares of IDEXX Laboratories by 1,475.0% during the 3rd quarter. Johnson Financial Group Inc. now owns 63 shares of the company's stock worth $40,000 after acquiring an additional 59 shares during the last quarter. Finally, Kemnay Advisory Services Inc. purchased a new position in IDEXX Laboratories in the fourth quarter worth $54,000. 87.84% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on IDXX shares. Wall Street Zen cut IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Saturday, April 25th. Barclays reduced their target price on IDEXX Laboratories from $850.00 to $800.00 and set an "overweight" rating for the company in a report on Thursday, February 5th. Piper Sandler decreased their price target on IDEXX Laboratories from $775.00 to $750.00 and set a "neutral" rating on the stock in a research report on Monday, February 9th. Weiss Ratings reissued a "hold (c+)" rating on shares of IDEXX Laboratories in a report on Monday, April 27th. Finally, BTIG Research cut their price objective on shares of IDEXX Laboratories from $830.00 to $800.00 and set a "buy" rating for the company in a research report on Tuesday, February 3rd. Seven analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $751.00.

Key IDEXX Laboratories News

Here are the key news stories impacting IDEXX Laboratories this week:

• Positive Sentiment: Q1 beats — IDXX posted EPS of $3.47 vs. $3.42 consensus and revenue of $1.141B (up ~14% y/y), showing healthy top‑line growth that exceeded expectations and drove the initial rally. IDEXX Laboratories Announces First Quarter Results
• Positive Sentiment: Raised FY‑2026 outlook — management set EPS guidance of $14.45–$14.90 and revenue guidance roughly $4.7–$4.8B, which the market interpreted as a lift to 2026 expectations and supports the growth story. IDEXX Laboratories Announces First Quarter Results
• Positive Sentiment: Margin expansion & diagnostic momentum — analysts and coverage noted rising margins and strengthened diagnostics/innovation trends that underpin earnings leverage going forward. IDEXX Stock Up on Q1 Earnings & Revenue Beat, Margins Rise, '26 View Up
• Neutral Sentiment: Full disclosure available — the earnings call transcript and slide presentation are posted for investors to drill into segment details and management commentary on drivers and cadence. IDEXX Laboratories, Inc. (IDXX) Q1 2026 Earnings Call Transcript IDEXX Laboratories, Inc. 2026 Q1 - Results - Earnings Call Presentation
• Negative Sentiment: Valuation questions — coverage highlighted an 18.5% one‑year rally and elevated multiples (P/E and PEG), prompting debate on whether current price already reflects recovery and growth. Is It Too Late To Consider IDEXX Laboratories (IDXX) After Its 18.5% One-Year Rally?
• Negative Sentiment: Watch guidance nuance — while management raised its full‑year view overall, the EPS range sits near consensus and leaves execution risk if diagnostic growth or margin improvements slow; some headlines framed the change as modest. IDEXX claws down a beat as shares bound higher on a guidance hike

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.